Skip to main content

Table 1 DNA (%) presented in “head” and “tail” pre- and post-incubation with doxorubicin in breast cancer cell lines

From: Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer

  Control Cisplatin (1 μM)
  % DNA % DNA % DNA % DNA
(mean ± 1.96 S.E.) (mean ± 1.96 S.E.) (mean ± 1.96 S.E.) (mean ± 1.96 S.E.)
  in Head in Tail in Head in Tail
LoVo 83.55 ± 4.25 17.45 ± 4.12 89.28 ± 2.32 11.72 ± 2.29
HCT-15 78.58 ± 4.05 21.42 ± 4.05 92.35 ± 1.84 7.65 ± 1.83
HCT-116 84.92 ± 3.32 15.08 ± 3.27 92.50 ± 2.00 8.51 ± 1.88
HT55 82.17 ± 2.75 17.82 ± 2.75 90.60 ± 1.58 9.39 ± 1.51